TEEC Angel Fund

Eugene Zhang and Jinlin Wang serve as founding partners and the primary decision-makers. The partnership often includes other founding members of the Tsinghua Entrepreneur and Executive Club. Investment committee composition is not publicly documented in detail.

It operates as a traditional venture capital firm structured around a closed LP base drawn heavily from the Tsinghua diaspora. The fund is not a single-family office or a multi-family office. Capital comes from alumni entrepreneurs and affiliated corporate entities rather than a single family balance sheet.

Tsinghua affiliation is common but not a formal requirement. The network provides proprietary deal flow, but the fund has backed teams without direct university ties when the technical thesis and US-China bridge angle are strong. Portfolio company Ginkgo Bioworks, for example, was founded by MIT synthetic biologists.

Sourcing flows predominantly through the Tsinghua alumni network in Silicon Valley, which includes engineers, founders, and executives at major technology companies. The Beijing office supplements this by identifying companies seeking China market entry or Asia-based strategic investors. The fund rarely competes in open auction processes, instead securing allocations through warm introductions from network members.

TEEC Angel Fund does not reserve significant capital for follow-on rounds. Instead, it uses its Beijing network to introduce later-stage investors — often Chinese strategic funds, corporate venture arms, or US VCs seeking Asia syndicate partners. This handoff model means TEEC's ownership typically dilutes after Series A unless the general partners choose to raise special-purpose vehicles for individual breakout companies.

The fund has not publicly detailed internal adjustments since 2020. Public record indicates some LP and co-investor relationships remain cross-border, but the firm has not faced public disclosure of CFIUS-related portfolio disruptions. The structural challenge is inherent: its differentiation relies on bilateral flows that heightened regulatory scrutiny makes harder to maintain.

The fund's most prominent liquidity event was the 2021 public listing of Ginkgo Bioworks via a SPAC merger (per Reuters, 2021). Cista achieved unicorn status in China, though exit details remain private. Beyond these, the majority of exits have occurred through M&A transactions where terms were not publicly reported.